Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. (2018)

Peer-Reviewed Study · Christine G Skibinski; Tara Williamson; Gregory J Riggins · December 2018

Christine G Skibinski et al., 2018-12: Skibinski et al. report that mebendazole in the feed, alone and with a single 12 Gy dose, extends survival in an intracranial KT21MG1 malignant meningioma model.

A dose of 50 mg/kg MBZ plus a single dose of 12 Gy radiation can impede tumor growth and significantly increase survival in a Grade III intracranial model of malignant meningioma by decreasing Ki67 and increasing cleaved caspase-3 protein expression.

Christine G Skibinski et al., 2018-12: Skibinski et al. report that mebendazole in the feed, alone and with a single 12 Gy dose, extends survival in an intracranial KT21MG1 malignant meningioma model. Study type: intracranial rodent model of malignant meningioma (KT21MG1) plus meningioma cell lines. N: not stated in the abstract. Country: USA (Johns Hopkins). Dose: 50 mg/kg in a high-fat diet, ad libitum, from day 5 post-implantation; radiation 12 Gy single dose. Funder: US NIH R01 CA190223. Declared conflicts: 'Dr. Riggins is a founder of and holds equity in Benizole Therapeutics PBC. The results of the study discussed in this publication could affect the value of Benizole.' Comparator: radiation alone and untreated controls. Study type: animal.